Received Jun 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
All over itchy body rash; This non-serious case was reported by a consumer and described the occurrence of itchy rash in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 14-JAN-2026, the patient received the 1st dose of Shingrix. On 20-JAN-2026, 6 days after receiving Shingrix, the patient experienced itchy rash (Verbatim: All over itchy body rash). The patient was treated with prednisone, hydroxyzine hydrochloride (Hydroxyzine) and clobetasol propionate (Clobetasol). On 15-MAR-2026, the outcome of the itchy rash was resolved (duration 1 month 23 days). It was unknown if the reporter considered the itchy rash to be related to Shingrix. Additional Information: GSK Receipt Date: 10-JUN-2026 The patient had urgent care for all over itchy body rash, on 07-FEB-2026, prednisone followed up with PCM hydroxyzine, singular, followed up with dermatologist, prednisone, hydroxyzine, clobetasol. Rash abated mid MAR-2026. The batch number was not provided upon follow up with the reporter.